What are the side effects of bimetinib/bemetinib?

Binimetinib/Binimetinib is a kinase inhibitor drug mainly used to treat certain types of melanoma and non-small cell lung cancer. Kinase inhibitors work by blocking the activity of abnormal proteins that send reproductive signals to cancer cells, prompting them to grow and spread. Therefore, the use of bimetinib can effectively slow down or prevent the proliferation and spread of cancer cells, especially when surgical removal is difficult or the tumor has spread to other locations.

Often, bimetinib is combined with another drug, canafenib (Encorafenib), to increase the effectiveness of the treatment. This combination therapy has achieved significant results in patients with melanoma and non-small cell lung cancer, improving survival and quality of life. However, like many anti-cancer drugs, bimetinib's efficacy is accompanied by certain side effects.

In clinical studies, the most common adverse reactions in patients treated with bimetinib in combination with canafenib include fatigue, nausea, diarrhea, vomiting, musculoskeletal pain, abdominal pain, visual impairment, constipation, dyspnea, rash, and cough. The incidence rate of these side effects exceeds 25%, so patients may experience varying degrees of physical discomfort when receiving treatment. In addition, these side effects not only affect patients' daily activities, but may also have a negative impact on their mental state.

In addition to common adverse reactions, the use of bimetinib may also cause some serious adverse reactions, with an incidence rate of more than 2%, including bleeding, diarrhea, anemia, dyspnea, pneumonia, arrhythmia, infection, edema, myocardial infarction and pleural effusion, etc. These serious side effects require close monitoring and prompt treatment by doctors to ensure patient safety and health.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c3408ac-d401-4925-8a03-26591afbc240##